New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company’s commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant’s rhCollagen-based products and platforms.
“We are excited to welcome Bowman to the CollPlant leadership team as we scale our commercial operations and development programs,” said Yehiel Tal, Chief Executive Officer of CollPlant. “His deep expertise in collagen-based biomaterials, 3D bioprinting, and tissue engineering aligns perfectly with our growth strategy. Bowman’s proven track record in sales, product development, licensing, and operational execution will be instrumental as we grow our bioinks portfolio and expand rhCollagen sales to the research market as well as to strategic collaborators in the fields of regenerative and aesthetic medicine.”
Mr. Bagley joins CollPlant from Wasatch Biolabs, a genomics research company, where he served as Vice President and Fractional CxO, leading revenue operations and growth initiatives. Previously, he spent nearly a decade at Advanced BioMatrix, a global supplier of purified collagen and extracellular matrix products, where he served as Chief Executive Officer. During his tenure, he held leadership roles across product development, business development, and global sales, helping to establish the company as a leading supplier in the research and tissue engineering space.
In addition to his leadership roles, Mr. Bagley has advised life science companies on go-to-market strategies, commercial partnerships, and scaling operations. He is also an active angel investor with NuFund Venture Group, where he conducts due diligence on emerging biotech ventures.
“I am honored to join CollPlant at such an exciting time in its growth trajectory,” said Bowman Bagley. “CollPlant’s recombinant human collagen platform represents a transformative advancement in regenerative medicine and biomaterials. I’m eager to contribute to the company’s mission and help accelerate the commercial success of its innovative product portfolio, while driving long-term value for shareholders.”
Mr. Bagley holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of Utah.
